Últimas noticias sobre Evolv Technologies (NASDAQ:EVLV) Bolsa

Evolv Technologies

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Evolv Technologies Holdings, Inc. - Class A Common Stock

Evolv Technologies Holdings Inc

Evolv Technologies Holdings, Inc. - Warrant

<a href="https://www.globenewswire.com/Tracker?data=Xh3dnx7bd9ZsfQVfM-pJGVrq5AFikCMwonz-rxJuGZM7iIAshhT3szNwdNmLV8wH1Mva7G52IZeQmBnXmgnTflhvqHVULt4s7bTo0ZOx3Gw=">Mullen Automotive, Inc.</a> (NASDAQ:<a href="https://www.globenewswire.com/Tracker?data=EfgpfV9WrmnsUtly_LfIvEM-3lCJKaQ9foV0byhXKXdwio9oe8M3vTFSG5pZt9Y8AcBwV6fQPVX3NjLqExLdRtqqQ3OYYiiJUIjI5QyCSZ6fI--EPQ-6CDHzQBom9zgY"> MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that the Company is accepting cryptocurrency ("crypto"), including Bitcoin and the $TRUMP meme coin, for the purchase of both Mullen and Bollinger commercial electric vehicles.
The Company is currently one of the only vehicle manufacturers to accept cryptocurrency as payment form on vehicle purchases. The Company is also investigating acceptance of additional types of crypto, including other popular meme and stable coins.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

MULN

Mullen Automotive Now Accepting Bitcoin And $TRUMP Meme Coin For EV Purchases; Explores More Crypto Options

ZYXI

Zynex Secures UK Patent For Multiparameter, Noninvasive Sepsis Monitor

WIIM

LFWD

Lifeward shares are trading lower after the company announced the pricing of a $2.6 million public offering of 4 million shares and warrants at a combined price of $0.65 per share and associated ordinary warrant.

Baird analyst Colleen Kusy maintains Nuvalent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) with a Outperform and raises the price target from $105 to $112.

Price Target

Analyst Ratings

NUVL

Baird Maintains Outperform on Nuvalent, Raises Price Target to $112

BLNE

Beeline Holdings shares are trading higher after the company announced its subsidiary, Beeline Title holdings, closed its first crypto real estate transactions.

BMBL

BMBL stock has given up its prior loss. Bumble share were trading lower after the company announced it is reducing the size of its team.

Shares of KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) traded higher on Tuesday after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46063325/kb-home-q2-earnings-revenue-eps-beat-estimates-homebuilder-lowers-2025-housing-revenue-outlook-as-market-conditions-soften">upbeat fiscal second-quarter revenues a day earlier.</a>
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
BofA Securities On KB Home
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/596530e4988ca80001209fc0/rafe-jadrosich">Analyst Rafe Jadrosich</a> maintained a Buy rating, while cutting the price target from $58 to $54.
Although KB Home reported in-line earnings for its fiscal second quarter, it lowered its full-year revenue and margin guidance, Jadrosich said in a note. The company had net orders of 3,500, missing expectations and representing a 13% year-on-year decline, he added.
"KBH continued to lower base home prices in underperforming communities," the analyst wrote. Management reduced their revenue guidance from $6.6 billion-$7 billion to $6.3 billion-$6.5 billion and their margin guidance from 19.2%-20% to 19%-19.4% "due to lower deliveries and regional mix," he further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
JPMorgan On KB Home
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f9fdc60bd991000159a4c3/michael-rehaut">Analyst Michael Rehaut</a> reiterated a Neutral rating on the stock.
Although KB Home reported in-line earnings, its gross margin contracted by 60 basis points (bps) sequentially and by 150 bps year-on-year to 19.7%, Rehaut said. The company's absorption rate, which indicates the pace of sales, declined to 17%, worse than expectations of a decline of 14%.
Management lowered their full-year guidance "across most metrics," the analyst wrote. The company's lowered gross margin outlook reflects a year-on-year contraction between 170 and 210 bps, he further stated.
KBH Price Action: Shares of KB Home were up 4.74% to $82.44 on Tuesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46078855/kb-home-analysts-slash-their-forecasts-after-q2-earnings">KB Home Analysts Slash Their Forecasts After Q2 Earnings</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Earnings

Reiteration

KB Home Stock Jumps After Q2 Report, But Forecasts Leave Analysts Divided

<a href="https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits" title="https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits">https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits</a>

Short Sellers

Trading Ideas

Watching CTO Realty Growth; Wolfpack Research Issues Report On The Co Stating They Are Short

RSLS

ReShape Lifesciences shares are trading higher after the company announced it was granted an institutional patent from the Australian Patent Office for its Diabetes Neuromodulation technology.

Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company's ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately $2.6 million before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the ordinary warrants, if fully exercised on a cash basis, will be approximately $2.6 million. No assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from this offering for its continuing commercial efforts, working capital and general corporate purposes.

Offerings

Lifeward Prices $2.6M Public Offering Of 4M Shares And Warrants At A Combined Price Of $0.65

FBRX

Forte Biosciences shares are trading lower after the company announced the pricing of a $75 million public offering.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">248.38</td>
<td align="right">1.14</td>
<td align="right">0.46</td>
<td>21.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.60</td>
<td align="right">0.01</td>
<td align="right">0.01</td>
<td>4.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.1153</td>
<td align="right">-0.145</td>
<td align="right">-0.35</td>
<td>602</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">133.6200</td>
<td align="right">-0.160</td>
<td align="right">-0.12</td>
<td>6.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.2800</td>
<td align="right">-0.050</td>
<td align="right">-0.07</td>
<td>2.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.8700</td>
<td align="right">-0.040</td>
<td align="right">-0.05</td>
<td>31.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.5700</td>
<td align="right">-0.010</td>
<td align="right">-0.02</td>
<td>119.6K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Leading And Lagging Sectors For June 25, 2025

PRTG

Portage Biotech shares are trading higher after the company announced it regained Nasdaq compliance.

Four new interventional labs across Northlake and Southlake campuses enable minimally invasive procedures with improved imaging, reduced radiation and enhanced clinician and patient experience
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.philips.com%2Fnewscenter&amp;esheet=54281780&amp;newsitemid=20250625531921&amp;lan=en-US&amp;anchor=Royal+Philips&amp;index=1&amp;md5=8e44efa717d8e6887b8fb3e1d7b53aa3">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmethodisthospitals.org%2F&amp;esheet=54281780&amp;newsitemid=20250625531921&amp;lan=en-US&amp;anchor=Methodist+Hospitals&amp;index=2&amp;md5=218329d9b042cc89650a358f72872ba8">Methodist Hospitals</a> today announced the healthcare provider's strategic investment in Philips' advanced portfolio of image-guided therapy (IGT) solutions that integrate imaging systems and software, with specialized diagnostic and therapeutic devices. The new interventional suites will support critical health needs within the community including active stroke treatment, oncology therapies, complex cardiovascular intervention and care for other prevalent health conditions.
Methodist Hospitals will utilize one Philips Azurion biplane for both routine and complex procedures – such as active stroke intervention – designed to speed up and improve minimally invasive treatment. The health system will also standardize care on two single plane labs for cardiovascular care and a multi-purpose lab for complex cardiovascular and interventional radiology procedures. The Philips Azurion system has been shown to improve operational and clinical efficiency in the interventional suite while maintaining high quality care and staff satisfaction, including a 17% reduction in procedure time, providing the ability to treat one more patient per day [1].

Biotech

General

Royal Philips And Methodist Hospitals Launch 4 Advanced Interventional Labs To Boost Minimally Invasive Procedures And Imaging Efficiency

WKSP

Worksport Announces  Nano-Grid System Pilot With A US Construction Group

DA Davidson analyst Gil Luria initiates coverage on ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Buy rating and announces Price Target of $1150.

Initiation

DA Davidson Initiates Coverage On ServiceNow with Buy Rating, Announces Price Target of $1150

Femasys Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc&#xAE; System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended polymer joins the earlier approval announced on March 13, 2025 for the delivery system component of FemBloc. The FemBloc System can now be marketed in the European Economic Area, which includes the 27 member states of the European Union and the 3 European Free Trade Association countries.

FEMY

Femasys Announces CE Mark Certification Under European Union Medical Device Regulation Of Class III FemBloc Blended Polymer Component

Eco Wave Power Global AB (publ) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>), a leading onshore wave energy developer, is pleased to announce that Inna Braverman, Founder and CEO of Eco Wave Power, and Ran Atias, VP of Engineering, held a strategic meeting with Terry Tamminen, CEO of AltaSea at the Port of Los Angeles, to officially agree upon the launch date and public unveiling of the first-ever onshore U.S. wave energy pilot project.
The historic launch event is scheduled to take place on Tuesday, September 9, 2025, on-site at AltaSea, and will mark a historic milestone in renewable energy innovation for the United States. The event is expected to draw key stakeholders from the clean energy sector, government, academia, and media, and will showcase the real-world implementation of Eco Wave Power's patented wave energy technology.
 &nbsp;

WAVE

Eco Wave Power Sets September 9 Launch For First Onshore U.S. Wave Energy Pilot At Port of Los Angeles

Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy
Initial Phase 1 clinical update shows early disease control in first HPV+ patient treated with APR-1051
DOYLESTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities&nbsp;while minimizing damage to healthy cells, today announced new preclinical data and a clinical update on APR-1051, the Company's next-generation oral WEE1 inhibitor, in human papillomavirus–positive (HPV+) head and neck squamous cell carcinoma (HNSCC).
These findings result from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center and support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations for biomarker-driven treatment of HPV+ HNSCC. "We are excited by the preclinical data generated by independent researchers, and the early clinical signal of APR-1051 in an HPV-positive cancer patient," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. "We believe that APR-1051 could offer significant differentiation in the competitive oncology landscape, as a single agent, as well as in combination with checkpoint inhibitors."

APRE

Aprea Therapeutics Presents APR-1051 Preclinical And Early Clinical Results In HPV+ Head And Neck Cancer

VEEV

Veeva Expands AWS Relationship

Press Releases

San Francisco Giants Deploy Latest Evolv Express® Gen2 Systems for 2025 Season

Partnership with Cosm Reinforces Evolv Technology's Sports Industry Position as Innovation Leader

Evolv Receives Expected Nasdaq Delinquency Notification

Evolv Technology Appoints Chris Kutsor as Chief Financial Officer

Evolv Technology Completes Restatement of Previously Issued Financial Statements and Reports Third Quarter, Fourth Quarter and Full Year 2024 Financial Results

Comments

Evolv Technologies

Noticias

Últimas noticias sobre Evolv Technologies (NASDAQ:EVLV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL